Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs SoundHound AI Inc (SOUN) Price & Performance

Moderna, Inc.Trade
SoundHound AI IncTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs SoundHound AI Inc — how do they compare? Moderna, Inc. trades at $137.1 (market cap $54.14B), while SoundHound AI Inc trades at $6.47 (market cap $2.92B). The key difference: Moderna, Inc. is far larger — about 18.5× SoundHound AI Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.

MRNASOUN
Market Cap
$54.14B$2.92B
Sector
HealthTechnology
52-Week High
$174.38$21.40
52-Week Low
$22.36$5.70
Enterprise Value
$50.29B$2.72B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.

The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.

SoundHound AI Inc

SoundHound AI (SOUN) trades at $6.57, down 2.52% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company demonstrates strong revenue growth with Q2 2026 revenue up 45% year-over-year to $61.9 million, though it remains unprofitable with a -67.45% net income margin. Recent completion of the LivePerson acquisition creates a leading conversational AI platform with projected 2026 revenue of $230-260 million.

While analyst consensus remains bullish with 75% buy ratings and $8.50 price target (29% upside), significant risks include persistent losses, high valuation multiples (P/S 13.57), and negative cash flow projections for 2026. The stock's heavy short interest (nearly 40%) reflects market skepticism about profitability timeline despite strong top-line growth.

Returns comparison

Trailing returns across standard periods

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About SoundHound AI Inc

SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.

Read more on SOUN